Travis Dalton Purchases 1,950 Shares of Claritev (NYSE:CTEV) Stock

Claritev (NYSE:CTEV) CEO Travis Dalton purchased 1,950 shares of Claritev stock in a transaction dated Friday, August 28th. The shares were acquired at an average cost of $38.48 per share, for a total transaction of $75,036.00. Following the completion of the transaction, the chief executive officer owned 52,322 shares of the company’s stock, valued at approximately $2,013,350.56. This represents a 3.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Travis Dalton also recently made the following trade(s):

• On Thursday, August 27th, Travis Dalton acquired 4,500 shares of Claritev stock. The stock was acquired at an average cost of $38.81 per share, with a total value of $174,645.00.

Claritev Price Performance

Shares of CTEV stock opened at $39.37 on Wednesday. Claritev has a 1-year low of $11.50 and a 1-year high of $74.07. The stock’s fifty day moving average price is $31.62 and its 200 day moving average price is $25.00. The company has a market cap of $667.32 million, a price-to-earnings ratio of -2.31 and a beta of 0.87.

Claritev (NYSE:CTEV) last released its quarterly earnings results on Friday, August 7th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of ($4.10) by $5.51. The business had revenue of $257.48 million during the quarter. As a group, equities research analysts anticipate that Claritev will post -15.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CTEV shares. Piper Sandler reaffirmed an “overweight” rating and issued a $73.00 price objective on shares of Claritev in a research report on Wednesday, August 12th. Citigroup restated a “buy” rating and set a $45.00 price target (up from $40.00) on shares of Claritev in a research note on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Barclays reiterated an “overweight” rating and set a $40.00 price objective (up from $28.00) on shares of Claritev in a research note on Thursday, August 20th. Finally, Wells Fargo & Company boosted their price objective on shares of Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, August 12th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Arini Captial Management Ltd acquired a new stake in shares of Claritev during the 4th quarter worth approximately $64,291,000. Public Investment Fund acquired a new position in shares of Claritev in the 2nd quarter valued at $43,703,438. Beach Point Capital Management LP lifted its stake in shares of Claritev by 77.4% in the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock valued at $32,276,000 after purchasing an additional 329,424 shares during the period. Vanguard Group Inc. purchased a new stake in Claritev during the third quarter worth $27,483,000. Finally, Charles Schwab Investment Management Inc. grew its position in Claritev by 17.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 262,318 shares of the company’s stock valued at $11,214,000 after buying an additional 39,845 shares during the period. 87.15% of the stock is owned by institutional investors and hedge funds.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.